scholarly journals Body composition, but not insulin resistance, influences postprandial lipemia in patients with Turner's syndrome

Author(s):  
Rodrigo de Azeredo Siqueira ◽  
Aluana Santana Carlos ◽  
Joana Costa d'Avila ◽  
Adalgiza Mafra Moreno ◽  
Estela Luz Alves ◽  
...  
1991 ◽  
Vol 72 (4) ◽  
pp. 832-836 ◽  
Author(s):  
SONIA CAPRIO ◽  
SUSAN BOULWARE ◽  
MICHAEL DIAMOND ◽  
ROBERT S. SHERWIN ◽  
T. O. CARPENTER ◽  
...  

1994 ◽  
Vol 33 (9) ◽  
pp. 560-563
Author(s):  
Yoshitaka KUMON ◽  
Kunihiko HISATAKE ◽  
Tadashi SUEHIRO ◽  
Ryota SUMIYOSHI ◽  
Kozo HASHIMOTO

2006 ◽  
Vol 65 (2) ◽  
pp. 69-75 ◽  
Author(s):  
Burak Salgin ◽  
Rakesh Amin ◽  
Kevin Yuen ◽  
Rachel M. Williams ◽  
Peter Murgatroyd ◽  
...  

1997 ◽  
Vol 82 (8) ◽  
pp. 2570-2577
Author(s):  
Claus Højbjerg Gravholt ◽  
Rune Weis Naeraa ◽  
Sanne Fisker ◽  
Jens Sandahl Christiansen

The objectives of this study were to 1) study the GH-insulin-like growth factor (IGF) axis in adult untreated Turner’s syndrome compared to that in age-matched controls, 2) examine the effects of sex hormone substitution on this axis, 3) study the effects of route of administration of 17β-estradiol on the measured variables, and 4) examine the effects of sex steroids on hepatic function in Turner patients. Twenty-seven patients with Turner’s syndrome were evaluated before and during sex hormone replacement, and an age-matched control group (n = 24) was evaluated once. Main outcome variables were GH and other measures of the GH-IGF axis, body composition, maximal oxygen uptake, sex hormone-binding globulin, and hepatic enzymes and proteins. The integrated 24-h GH concentration (IC-GH; micrograms per L/24 h) was reduced in women with Turner’s syndrome (T) compared to controls [C; mean ± sd, 18.3 ± 12.0 (T) vs. 37.2 ± 29.7 (C); P = 0.007]. However, multiple regression revealed that fat-free mass (FFM) and maximal oxygen uptake were significant explanatory variables (joint r = 0.77; P < 0.0005), accounting for 60% of the variance in the 24-h IC-GH. This association was also present in controls. After adjustment for these two variables, any difference in GH concentration between Turner patients and controls disappeared. Serum IGF-I and IGF-II were identical in Turner patients and controls despite the difference in 24-h IC-GH. The level of GH-binding protein (GHBP; nanomoles per L) was higher in Turner women [1.87 ± 0.72 (T) vs. 1.22 ± 0.33 (C); P = 0.0005]; after adjustment for FFM, the difference in GHBP levels disappeared between Turner patients and controls. During sex hormone treatment a significant increase was seen in the 24-h IC-GH (P = 0.02), FFM (percentage of weight; P < 0.0005) and maximal oxygen uptake (milliliters of O2 per kg/min; P = 0.02). Serum IGF-I was unchanged, whereas serum IGF-II (micrograms per L) decreased significantly [Turner, basal (TB), vs. Turner, treatment (TT), 860 ± 135 vs. 823 ± 150; P = 0.04]. Alanine aminotransferase (units per L), γ-glutamyl transferase (units per L), and alkaline phosphatase (units per L) were significantly elevated during the basal study period, and all decreased during treatment [alanine aminotransferase, 55 ± 55 (TB) vs. 30± 20 (TT; P = 0.006); γ-glutamyl transferase, 92 ± 98 (TB) vs. 43 ± 65 (TT; P = 0.003); alkaline phosphatase, 211 ± 113 (TB) vs. 175± 54 (TT); P = 0.06]. The route of administration of 17β-estradiol did not affect its actions. In conclusion, we found the GH-IGF axis in Turner’s syndrome to be normal, with body composition and physical fitness exerting the same modifying effects on this axis as seen in the normal population. Sex hormone replacement in Turner’s syndrome is associated with normalizing effects on the GH-IGF axis, body composition, physical fitness, and hepatic function. The lowering of hepatic enzymes is a surprising and hitherto undiscovered action of sex steroids. Finally, the route of administration of 17β-estradiol is of minor importance in Turner’s syndrome.


Author(s):  
A. González-Angulo ◽  
S. Armendares-Sagrera ◽  
I. Ruíz de Chávez ◽  
H. Marquez-Monter ◽  
R. Aznar

It is a well documented fact that endometrial hyperplasia and adenocarcinoma may develop in women with Turner's syndrome who had received unopposed estrogen treatment (1), as well as in normal women under contraceptive medication with the sequential regime (2). The purpose of the present study was to characterize the possible changes in surface and glandular epithelium in these women who were treated with a sequential regime for a period of between three and eight years. The aim was to find organelle modifications which may lead to the understanding of the biology of an endometrium under exogenous hormone stimulation. Light microscopy examination of endometrial biopsies of nine patients disclosed a proliferative pattern; in two of these, there was focal hyperplasia. With the scanning electron microscope the surface epithelium in all biopsies showed secretory cells with microvilli alternating with non secretory ciliated cells. Regardless of the day of the cycle all biopsies disclosed a large number of secretory cells rich in microvilli (fig.l) with long and slender projections some of which were branching (fig. 2).


1974 ◽  
Vol 77 (1_Suppl) ◽  
pp. S48 ◽  
Author(s):  
F. Majewski ◽  
J. R. Bierich ◽  
M. Barz ◽  
W. F. Haberlandt ◽  
M. Stoeckenius

1986 ◽  
Vol 113 (4_Suppl) ◽  
pp. S157-S163 ◽  
Author(s):  
K.W. KASTRUP ◽  
_ _

Abstract Early therapy with a low dose of estrogen (estradiol-17β) was given to 33 girls with Turner's syndrome (T.s.) for a period of 4 years. The dose (0.25-2 mg/day) was adjusted every 3 months to maintain plasma estradiol in the normal concentration range for bone age. Growth velocity was compared with that of untreated girls with T.s. All girls were above age 10 years. Bone age was below 10 years in 11 girls (group I) and above 10 years in 22 girls (group II). Growth velocity in the first year of treatment in group I 7.5 ± 1.3 cm (SD) with mean SD score (SDS) of +4.3 and in group II 4.9 ± 1.3 with mean SDS of +3.5. Growth velocity decreased in the following years to 1.6 ± 1.0 cm, SDS -1.44 in group I and 0.9 ± 0.6cm, SDS -2.34 in group II during the fourth year. Withdrawal bleeding occurred in 16 girls of group II after the mean of 23 (range 15-33) months and in 3 girls of group I after 15 to 51 months of treatment. The treatment did not cause an inappropriate acceleration of pubertal development. Breast development appeared in most girls by 3 months of treatment. Pubic hair appeared by 12 months of treatment in group I; it was present in most girls in group II at start of treatment. Final height is known for 12 girls of group II; it was 144.2 ± 4.5 cm. The final height as predicted at the start of therapy was 142.2 ± 5.3 cm. Bone age advanced in the first year of treatment by 2 years. Early treatment with small doses of estrogens induces a growth spurt and normalizes the events of puberty. This will presumably decrease the psychological risks associated with abnormally delayed development.


Sign in / Sign up

Export Citation Format

Share Document